News & Updates

In the treatment of patients with refractory cutaneous dermatomyositis, the cannabinoid receptor type 2 agonist lenabasum yields good outcomes in terms of efficacy and safety, as indicated by improvements in disease activity and no increased risk of serious or severe adverse events, according to the results of a phase II study.

Treatment with stereotactic body radiotherapy (SBRT) results in encouraging palliative responses, with >80 percent of patients having initial pain responses and 60 percent durable pain responses, according to a recent study. Dose escalation can help improve initial complete response (CR) rates.

Children who were on a vegetarian diet had comparable measures of growth and nutrition compared with children on a nonvegetarian diet. However, those on a vegetarian diet had higher odds of being underweight, according to a recent study.

A long-term safety analysis of repeated diazepam nasal sprays finds acceptable rates of treatment-emergent adverse events in children and adolescents, with such side effects being comparably common between the two age groups.

Having a fourth dose of COVID-19 vaccine (ie, second booster dose) substantially protects against severe illness in face of the Omicron variant, compared with only three doses of vaccine that were given more than 4 months earlier, according to data from the Israeli Ministry of Health database.